Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments

Executive Summary

Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.

Advertisement

Related Content

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
The Year's Clinical Trials In Review: Big Misses In 2017
Argos Not Stopping Cancer Vaccine Study Despite Futility
Prostate Cancer Vaccines: What’s In The Pipeline?
Argos Nears Phase III Results For Precision Cancer Immunotherapy
Agenus dives deeper into checkpoint inhibitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098276

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel